Full encapsulation of oncolytic virus using hybrid erythroctye-liposome membranes for augmented anti-refractory tumor effectiveness. (December 2022)

• Record Type: Journal Article
• Authors: Huang, Hanwei; Sun, Mengchi; Liu, Mingyang; Pan, Siwei; Liu, Pengfei; Cheng, Zhenguo; Li, Jia; Xu, Huimian; Liu, Funan; Pang, Zhiqing
• Is Part Of: Nano today. Volume 47(2022)
• Publication Date: 2022-12
• Subjects: Oncolytic virus -- Erythroliposome -- Hybrid nanovesicle -- Antigen shielding -- Camouflage; Nanotechnology -- Periodicals; Nanosciences -- Périodiques; 620.505
• DOI: 10.1016/j.nantod.2022.101671
• Languages: English
• ISSNs: 1748-0132

Abstract

Abstract: Intravenous delivery of oncolytic virus (OVs) is promising in cancer treatment. Unfortunately, fast clearance of OVs and the severe cytokine release syndrome impede its wide application. It has been shown that nanoparticles coated with cell membranes display less toxicity and slower clearance. However, different from conventional nanoparticles, the characteristic spike-like structure and abundant antigens on the surface make it difficult for intravenously delivered OVs to take advantage of cell membrane coating to shield their surface antigens. To overcome this challenge, we, for the first time, used erythrocyte-lipid hybrid membrane vesicle (erythroliposome) to fully encapsulate OVs for their intravenous delivery. We found that adding artificial membranes to cell membranes reduced the fluidity of the membranes, leading to an extraordinary shielding effect on OV antigens. Consequently, circulation of OVs was significantly prolonged and their oncolytic efficacy to metastatic and refractory tumors was markedly enhanced. Graphical Abstract: Erythroliposome fully cover ad11 and reduce the exposure of ad11 antigens and enhance the anti-tumor efficacy of ad11. ga1 Highlight: We firstly found that only cell membranes or liposomes showed no effect on shielding the antigen of oncolytic virus (OVs). We firstly used erythroliposomes formed by fusing liposomes with RBC membranes to fully coat OVs. We firstly treat metastatic tumors successfully by intravenous delivery of OVs. We firstly solved the problem that neutralizing antibodies produced during multiple OV injections reduced the anti-tumor efficacy of OVs.